Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer
NCT04806464
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Liver Cancer
Interventions
DRUG:
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
Sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.